الفهرس 
الفصل الاوليوجد فقط 14 صفحة متاحة للعرض العام
 |  | from | 242 |  |  |
| | | from | 242 | | |
المستخلص
Summary
Pityriasislichenoides is an uncommon dermatological disease of the skin. It is presented in three different forms: pityriasislichenoidesetvarioliformisacuta (PLEVA), pityriasislichenoideschronica (PLC), and febrile ulceronecroticMucha-Habermann disease (FUMHD). Each form is shown in a different presentation. Each form can occur alone or evolve from the other. Pityriasislichenoides affects roughly 1 in 2000 people per year. It can occur at any age, but it shows a slight predilection to males in late childhood.
PLC is more common than the other forms. It shows a milder presentation compared with PLEVA and FUMHD. It can be presented as an oval, red to brown papular eruption over the trunk, thighs, and upper arms with a fine scale that adherent at the center and peels at the periphery (mica like scale). It usually does not scar. Hypopigmented patches are another presentation of the disease. PLC shows a relapse and remission course over the years.
The exact etiology of PL is not fully understood. But the presence of T cells in the skin of PL patients suggests the immune theory of PL. As the genetically susceptible individuals elicit an inappropriate immune reaction to foreign agents, such as a virus or medication, which results in inflammation in the skin.Pityriasislichenoides has been seen in association with many illnesses, including streptococci, HIV, chickenpox, Epstein-Barr virus, cytomegalovirus, and hepatitis C. Some medications, such as antihistamines, estrogen-progesterone therapy, and the measles vaccine, have been implicated in pityriasislichenoides.
The diagnosis of PLC is made through full history-taking regarding the rash, precipitating factors such as infection or medication, and a skin biopsy of the lesion. Blood tests are usually normal except for the specific tests done to diagnose the triggering infection.
Treatment of PLC includes many lines of treatment, such as phototherapy, systemic antibiotics, topical steroids, topical immune modulators, and systemic immune suppressants for severe prolonged cases.
This study is an intervention study. It was carried out on34 patients with PLC who attended the Dermatology Outpatient Clinic of Al-Hussain University Hospital and “Badr” Hospital Helwan University in the period between 2020 to 2022.
All participants were subjected to full history taking, a complete general examination, and a local dermatologic examination.
Photography of the lesions has been taken before starting the Excimer light sessions, every month during treatment, and at the end of the study.
Excimer light sessions were taken by the Exclite micro machine (from Italy) at a rate of two sessions per week until complete recovery, or for a maximum of six months. The effectiveness of the excimer light had been measured by comparing photos of PLC lesions under excimer light sessions to photos that had been taken at the beginning of the study.
At the end of the study, 31 (91.2%) out of 34 patients reached a complete response, which is defined as more than 90% resolution of the skin lesions (papulosquamous and plaque lesions). With minimal adverse effects in the form of erythema and irritation in a few patients, and none of them discontinued the treatment as a result of the adverse effects